
CervoMed Inc (CRVO) Stock Forecast & Price Target
CervoMed Inc (CRVO) Analyst Ratings
Bulls say
CervoMed Inc. has demonstrated a positive financial trajectory, evidenced by a strengthened cash position of $38.9 million as of December 31, 2024, which supports its operational runway into mid-2026. The encouraging results from the 16-week extension phase of the RewinD-LB Phase 2b trial for neflamapimod show statistically significant clinical benefits, enhancing the company’s outlook for successful treatment of dementia with Lewy bodies. With increased investment in research and development, reflected in R&D expenses rising to $18.8 million, CervoMed is well-positioned for continued clinical advancement and corporate development.
Bears say
CervoMed Inc has experienced setbacks in its clinical trials, particularly with the RewinD-LB study, where suboptimal drug concentrations in trial capsules led to disappointing initial results. The company faces significant financial risks as it has yet to generate revenue from any marketable products and has consistently incurred losses since its inception. Additionally, there is heightened competition from both existing and emerging therapies addressing similar conditions, which could further hinder CervoMed's ability to penetrate the market and achieve sustainable pricing.
This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.
CervoMed Inc (CRVO) Analyst Forecast & Price Prediction
Start investing in CervoMed Inc (CRVO)
Order type
Buy in
Order amount
Est. shares
0 shares